Trending Topic

11 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Lung cancer is the second most common type of cancer worldwide and in the USA, with its incidence varying depending on geographic and socioeconomic factors.1–3 According to data from the Global Cancer Observatory: Cancer Incidence, Mortality and Prevalence (GLOBACAN) database, an estimated 2.48 million new cases of lung cancer were reported in 2022.4,5 Although lung cancer rates in the […]

Ahmet Sezer, ESMO 2020 – Cemiplimab in Non-small Cell Lung Cancer and the EMPOWER-Lung 1 Trial

Ahmet Sezer
Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Nov 2nd 2020

It was a pleasure to meet Dr Ahmet Sezer to discuss the clinical development of cemiplimab as a potential treatment for non-small cell lung cancer and key safety and efficacy findings from the EMPOWER- Lung 1 study. The late-breaking abstract, ‘EMPOWER-Lung 1: Phase 3 first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%’ (LBA52) was presented at the Virtual 2020 ESMO Congress, 19–21 September 2020.

Questions

  1. What have been the challenges of using immune checkpoint inhibitor monotherapies in the first-line treatment of non-small cell lung cancer (NSCLC)? (0:05)
  2. What were the aims, design and eligibility criteria of the EMPOWER-Lung 1 study? (1:43)
  3. What were the efficacy and safety findings of the study? (2:59)
  4. What will be the impact of these findings on clinical practice? (3:56)
  5. What will be the next step in the clinical development of cemiplimab? (4:20)

Speaker Disclosures: Dr Ahmet Sezer has nothing to disclose in relation to this video interview.

Support: Interview and filming supported by Touch Medical Media Ltd. The EMPOWER-Lung 1 study was funded by Regeneron Pharmaceuticals, Inc. and Sanofi.

Filmed in coverage of the Virtual 2020 ESMO Congress.

 

 

 

 

 

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup